文献速递儿科与产科急症重症综合管理与镇静镇痛

联合蛋白与mRNA生物标志物改进儿童脓毒性休克风险分层:PERSEVERE-XP

Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01
一句话结论PERSEVERE-XP联合蛋白与mRNA标志物,对儿童脓毒性休克28天死亡风险分层优于PERSEVERE,推导队列AUC 0.90、验证队列AUC 0.96。

该研究在既往PERSEVERE模型基础上,纳入68个先前未考虑的死亡风险评估基因,通过变量缩减识别出18个与TP53相关的基因网络,与PERSEVERE死亡概率结合,用分类回归树方法在307例儿童脓毒性休克患者中推导出PERSEVERE-XP模型,并在77例独立队列中验证。推导队列AUC为0.90(95%CI 0.85-0.95),验证队列AUC为0.96(95%CI 0.91-1.0),均优于PERSEVERE。作者认为PERSEVERE-XP可能具有临床 utility,并提示TP53相关的细胞分裂、修复和代谢在脓毒性休克病理生理中可能发挥作用。

要点

  • PERSEVERE-XP在307例推导队列中区分儿童脓毒性休克存活与死亡者的AUC为0.90(95%CI 0.85-0.95)。
  • 在77例独立验证队列中,PERSEVERE-XP的AUC为0.96(95%CI 0.91-1.0)。
  • PERSEVERE-XP的AUC优于PERSEVERE。
  • 变量缩减识别出18个与TP53相关的死亡风险评估基因网络,与PERSEVERE死亡概率结合构建模型。
  • 作者认为PERSEVERE-XP提供死亡风险分层,可能具有临床 utility。

适用人群与场景

  • 儿童脓毒性休克患者,用于28天死亡风险分层。

研究设计与关键结果

  • 研究类型:在既往PERSEVERE模型基础上推导并验证新模型PERSEVERE-XP。
  • 推导队列n=307,采用分类回归树方法构建28天死亡风险分层模型。
  • 验证队列n=77,用于测试推导出的PERSEVERE-XP。
  • 变量缩减识别出18个与TP53相关的死亡风险评估基因网络构成。
  • 推导队列中PERSEVERE-XP区分存活与死亡者的AUC为0.90(95%CI 0.85-0.95)。
  • 验证队列中AUC为0.96(95%CI 0.91-1.0)。
  • PERSEVERE-XP的AUC优于PERSEVERE。

证据类型、等级与局限

  • 证据类型:基于既往模型的推导与独立验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为PERSEVERE-XP提供死亡风险分层,可能具有临床 utility。
  • PERSEVERE-XP显著改善PERSEVERE,并提示TP53相关的细胞分裂、修复和代谢在脓毒性休克病理生理中可能发挥作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: We previously derived and validated the Pediatric Sepsis Biomarker Risk Model (PERSEVERE) to estimate baseline mortality risk in children with septic shock. The PERSEVERE biomarkers are serum proteins selected from among the proteins directly related to 80 mortality risk assessment genes. The initial approach to selecting the PERSEVERE biomarkers left 68 genes unconsidered.

OBJECTIVES: To determine if the 68 previously unconsidered genes can improve upon the performance of PERSEVERE and to provide biological information regarding the pathophysiology of septic shock.

METHODS: We reduced the number of variables by determining the biological linkage of the 68 previously unconsidered genes. The genes identified through variable reduction were combined with the PERSEVERE-based mortality probability to derive a risk stratification model for 28-day mortality using classification and regression tree methodology (n = 307). The derived tree, PERSEVERE-XP, was then tested in a separate cohort (n = 77).

MEASUREMENTS AND MAIN RESULTS: Variable reduction revealed a network consisting of 18 mortality risk assessment genes related to tumor protein 53 (TP53). In the derivation cohort, PERSEVERE-XP had an area under the receiver operating characteristic curve (AUC) of 0.90 (95% confidence interval, 0.85-0.95) for differentiating between survivors and nonsurvivors. In the test cohort, the AUC was 0.96 (95% confidence interval, 0.91-1.0). The AUC of PERSEVERE-XP was superior to that of PERSEVERE.

CONCLUSIONS: PERSEVERE-XP combines protein and mRNA biomarkers to provide mortality risk stratification with possible clinical utility. PERSEVERE-XP significantly improves on PERSEVERE and suggests a role for TP53-related cellular division, repair, and metabolism in the pathophysiology of septic shock.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wong HR, Cvijanovich NZ, Anas N, et al. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP. Am J Respir Crit Care Med. 2017. PMID: 28324661. doi:10.1164/rccm.201701-0066OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。